U.S. Patents for Foundational CRISPR-Cas9 Technology Granted To Merck & Co.

Merck granted U.S. Patents for Foundational CRISPR-Cas9 Technology A
leading science and technology company, Merck, announced that in the
United States, two of its CRISPR-Cas9-assisted genome-editing patents
have been allowed. In their work to advance and protect gene therapy
development programs, these allowances provide Merck with the
opportunity to support U.S. scientists and researchers. The […]

The post U.S. Patents for Foundational CRISPR-Cas9 Technology Granted
To Merck & Co. appeared first on BioTecNika .

https://www.biotecnika.org/2020/05/merck-granted-us-patents-for-foundational-crispr-cas9-technology/

Biotech News

Comments

Popular posts from this blog

Pharma Production Executive Post Vacancy @ Intas

Pharos of Chaos

HILR Intersession: Mollie Crawford-Volk: Velazquez' "Las Meninas" and its Modern Progeny